The U.S. Food and Drug Administration (FDA) has paused a program that allowed companies from sending American DNA to China to be used in clinical trials in a program first approved by the Biden administration, the agency announced this week.
The U.S. Food and Drug Administration (FDA) has paused a program that allowed companies from sending American DNA to China to be used in clinical trials in a program first approved by the Biden administration, the agency announced this week.